Summary:
Do you have Type 2 Diabetes and on at least one medication?
This study is to determine if LY2189265 is as safe and effective in reducing hemoglobin A1c (HbA1c) as compared to metformin in patients with Type 2 Diabetes.
Qualified Participants Must:
• Have type 2 diabetes for greater than or equal to 3 months and less than or equal to 5 years based on the disease diagnostic criteria (refer to the World Health Organization's [WHO]Classification of Diabetes)
•
Be treatment-naïve, not optimally controlled with diet and exercise alone, or are taking 1 oral antihyperglycemic medication (OAM) as monotherapy (excluding thiazolidinediones)
•
Be able and willing to tolerate a minimum dose of 1500 mg/day or up to 2000 mg/day of metformin
•
Have HbA1c greater than or equal to 6.5% to less than or equal to 9.5%
•
If a female of childbearing potential (not surgically sterilized and between menarche and 1-year postmenopausal): a)test negative for pregnancy at screening based on a serum pregnancy test, and b)agree to use a reliable method of birth control during the study and for 1 month following the last dose of study drug or c)not be breastfeeding
•
Have a stable weight (plus or minus 5%) greater than or equal to 3 months prior to screening
•
Have a body mass index (BMI) between 23 and 45 kg/m2, inclusive
•
Be well-motivated, capable, and willing to: a)perform SMBG testing b)learn how to self-inject treatment (LY2189265 or placebo)and c)maintain a study diary
Qualified Participants May Receive:
Study related care, diagnostic tests, and study medication at no cost. Payment for time and travel to the study center may be provided.